FrancophonIA/ELRC3.0 huggingface dataset:
English: Co-administration with the following medicinal products due to the potential for serious and/or lifethreatening adverse reactions (see section 4.5): colchicine, when used in patients with renal and/or hepatic impairment (antigout) (see section 4.5) sildenafil - when used for the treatment of pulmonary arterial hypertension (see sections 4.4 and 4.5 for co-administration for the treatment of erectile dysfunction), avanafil (PDE5 inhibitors) simvastatin and lovastatin (HMG-CoA reductase inhibitors) (see section 4.5) grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination (used to treat chronic hepatitis C infection) (see section 4.5) glecaprevir/pibrentasvir fixed dose combination (see section 4.5)
Croatian: Istodobna primjena sa sljedećim lijekovima zbog mogućih ozbiljnih i/ili po život opasnih nuspojava (vidjeti dio 4.5): kolhicin, kada se koristi u bolesnika s oštećenjem bubrežne i/ili jetrene funkcije (lijek za liječenje gihta) (vidjeti dio 4.5) sildenafil - kada se koristi za liječenje plućne arterijske hipertenzije (vidjeti dijelove 4.4 i 4.5 za istodobnu primjenu kod liječenja erektilne disfunkcije), avanafil (inhibitori PDE-5) simvastatin i lovastatin (inhibitori HMG-CoA reduktaze) (vidjeti dio 4.5)
English: Atazanavir with cobicistat
Croatian: Atazanavir s kobicistatom
English: Atazanavir, a component of EVOTAZ is excreted in human milk.
Croatian: Atazanavir, sastojak lijeka EVOTAZ izlučuje se u majčino mlijeko.
English: Cobicistat is a strong mechanism-based CYP3A inhibitor and a weak CYP2D6 inhibitor.
Croatian: Kobicistat je snažan inhibitor CYP3A temeljeno na mehanizmu i slab inhibitor CYP2D6.
English: Each film-coated tablet contains 300 mg of atazanavir (as sulphate), and 150 mg cobicistat.
Croatian: Jedna filmom obložena tableta sadrži 300 mg atazanavira (u obliku atazanavirsulfata) i 150 mg kobicistata.
English: Voriconazole should not be co-administered with EVOTAZ unless the benefit/risk assessment justifies the use of voriconazole (see section 4.4).
Croatian: Vorikonazol se ne smije primjenjivati istodobno s lijekom EVOTAZ, osim u slučajevima kada ocjena koristi/rizika opravdava primjenu vorikonazola (vidjeti dio 4.4).
English: There was an increase in the maximum PR interval compared to atazanavir alone.
Croatian: Primijećeno je produljenje maksimalnog PRintervala u usporedbi s atazanavirom primijenjenim samostalno.
English: Co-administration of EVOTAZ with grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination (used to treat chronic hepatitis C infection) is contraindicated because of the increase in grazoprevir and elbasvir plasma concentrations and potential for the increase in risk of ALT elevations associated with the increase in grazoprevir concentrations (see section 4.3 and Table 1).
Croatian: Istodobna primjena lijeka EVOTAZ s lijekovima koji sadrže grazoprevir, uključujući fiksnu kombinaciju elbasvir/grazoprevir (koja se koristi u liječenju kronične infekcije virusom hepatitisa C), kontraindicirana je zbog povišene koncentracije grazoprevira i elbasvira u plazmi, te postoji povećan rizik povišenja vrijednosti ALT-a zbog povišene koncentracije grazoprevira (vidjeti dio 4.3 i Tablicu 1).
English: There are no pharmacokinetic data available for atazanavir in combination with cobicistat in patients with renal insufficiency.
Croatian: Nema dostupnih farmakokinetičkih podataka o primjeni atazanavira u kombinaciji s kobicistatom u bolesnika s insuficijencijom bubrega.
English: No clinically relevant pharmacokinetic differences due to gender have been identified for atazanavir or cobicistat.
Croatian: Nisu identificirane klinički značajne farmakokinetičke razlike uvjetovane spolom koje bi bile povezane s atazanavirom ili kobicistatom.
English: Co-administration of EVOTAZ with medicinal products that inhibit CYP3A may decrease the clearance of atazanavir and cobicistat, resulting in increased atazanavir and cobicistat plasma concentrations (see section 4.5).
Croatian: Istodobna primjena lijeka EVOTAZ s lijekovima koji inhibiraju CYP3A može smanjiti klirens atazanavira i kobicistata, što za posljedicu može imati povišene plazmatske koncentracije atazanavira i kobicistata (vidjeti dio 4.5).
English: The demographic and baseline characteristics were similar between the atazanavir with cobicistat and atazanavir with ritonavir groups.
Croatian: Demografske i početne značajke bile su slične u skupini liječenoj atazanavirom i kobicistatom i onoj liječenoj atazanavirom i ritonavirom.
English: Atazanavir is metabolised principally by CYP3A4.
Croatian: Atazanavir se prvenstveno metabolizira putem CYP3A4.
English: Sofosbuvir 400 mg/velpatasvir, 100 mg/voxilaprevir 100 mg single dose* (atazanavir 300 mg with ritonavir 100 mg once daily)
Croatian: Sofosbuvir 400 mg/velpatasvir, 100 mg/voksilaprevir 100 mg u jednokratnoj dozi* (atazanavir 300 mg s ritonavirom 100 mg jednom dnevno)
English: These medicinal products include alfuzosin, amiodarone, astemizole, bepridil, cisapride, colchicine, dronedarone, ergot deriviatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine), lovastatin, orally administered midazolam, pimozide, quetiapine, quinidine, lurasidone, simvastatin, sildenafil (when used to treat pulmonary arterial hypertension), avanafil, systemic lidocaine, ticagrelor, terfenadine and triazolam.
Croatian: Među njih se ubrajaju alfuzosin, amiodaron, astemizol, bepridil, cisaprid, kolhicin, dronedaron, derivati ergota (npr. dihidroergotamin, ergometrin, ergotamin, metilergonovin), lovastatin, peroralno primijenjen midazolam, pimozid, kvetiapin, kinidin, lurasidon, simvastatin, sildenafil (kada se koristi za liječenje plućne arterijske hipertenzije), avanafil, sistemski lidokain, tikagrelor, terfenadin i triazolam.
English: Further dosage reduction of rifabutin to 150 mg twice weekly on set days is recommended for patients in whom the 150 mg dose 3 times per week is not tolerated.
Croatian: U bolesnika koji ne podnose dozu od 150 mg triput tjedno preporučuje se daljnje smanjenje doze rifabutina na 150 mg dvaput tjedno u određene dane.
English: If drospirenone/ethinyloestradiol is co-administered with atazanavir/cobicistat clinical monitoring is recommended due to the potential for hyperkalemia.
Croatian: Ako se drospirenon/etinilestradiol primjeni istodobno s atazanavir/kobicistatom preporučuje se kliničko praćenje zbog moguće hiperkalemije.
English: NAME OF THE MEDICINAL PRODUCT EVOTAZ 300 mg/150 mg film-coated tablets atazanavir/cobicistat
Croatian: EVOTAZ 300 mg/150 mg filmom obložene tablete atazanavir/kobicistat
English: EVOTAZ should be used with caution in patients with mild hepatic impairment.
Croatian: EVOTAZ treba primjenjivati uz oprez u bolesnika s blagim oštećenjem jetrene funkcije.
English: Co-administration of boceprevir and EVOTAZ is not recommended.
Croatian: Ne preporučuje se istodobna primjena boceprevira i lijeka EVOTAZ.
English: Simeprevir may increase atazanavir and/or cobicistat plasma concentrations.
Croatian: Simeprevir može povisiti plazmatske koncentracije atazanavira i/ili kobicistata.
English: It is especially important to mention these: medicines containing ritonavir or cobicistat (booster agents) other medicines to treat HIV infection (e.g. indinavir, didanosine, tenofovir disoproxil, tenofovir alafenamide, efavirenz, etravirine, nevirapine and maraviroc) boceprevir, simeprevir and sofosbuvir/velpatasvir/voxilaprevir (used to treat hepatitis C) sildenafil, vardenafil and tadalafil (used by men to treat impotence [erectile dysfunction]) if you are taking an oral contraceptive ("the Pill") any medicines used to treat diseases related to the acid in the stomach (e.g. antacids, H2-blockers like famotidine and proton pump inhibitors like omeprazole) disopyramide, flecainide, mexiletine, propafenone, digoxin, bosentan, amlodipine, felodipine, nicardipine, nifedipine, verapamil, diltiazem, metoprolol and timolol (medicines to lower blood pressure, to slow heart rate or to correct heart rhythm) atorvastatin, pravastatin, fluvastatin, pitavastatin and rosuvastatin (used to lower blood cholesterol) salmeterol (used to treat asthma) ciclosporin, tacrolimus and sirolimus (medicines to decrease the effects of body's immune system) certain antibiotics (rifabutin, clarithromycin) ketoconazole, itraconazole, voriconazole and fluconazole (antifungals) metformin (used to treat type 2 diabetes) warfarin, rivaroxaban and dabigatran (anticoagulants, used to reduce blood clots) irinotecan, dasatinib, nilotinib, vinblastine and vincristine (used to treat cancer) trazodone (used to treat depression)
Croatian: Osobito je važno da spomenete sljedeće: lijekove koji sadrže ritonavir ili kobicistat (pojačivače) druge lijekove za liječenje HIV infekcije (npr. indinavir, didanozin, tenofovirdizoproksil, tenofoviralafenamid, efavirenz, etravirin, nevirapin i maravirok) boceprevir, simeprevir i sofosbuvir/velpatasvir/voksilaprevir (koji se koriste u liječenju hepatitisa C) sildenafil, vardenafil i tadalafil (uzimaju ih muškarci za liječenje impotencije [erektilne disfunkcije]) ako uzimate oralnu kontracepciju ("pilule") bilo koji lijek za liječenje bolesti povezanih s kiselinom u želucu (npr. antacide, H2blokatore poput famotidina i inhibitore protonske pumpe poput omeprazola) dizopiramid, flekainid, meksiletin, propafenon, digoksin, bosentan, amplodipin, felodipin, nikardipin, nifedipin, verapamil, diltiazem, metoprolol i timolol (lijekovi za snižavanje krvnog tlaka, usporavanje rada srca ili ispravljanje srčanog ritma) atorvastatin, pravastatin, fluvastatin, pitavastatin i rosuvastatin (primjenjuju se za snižavanje razine kolesterola u krvi) salmeterol (primjenjuje se za liječenje astme) ciklosporin, takrolimus i sirolimus (lijekovi za smanjenje učinaka imunosnog sustava tijela) određene antibiotike (rifabutin, klaritromicin) ketokonazol, itrakonazol, vorikonazol i flukonazol (lijekovi za liječenje gljivičnih infekcija)
English: Common (may affect up to 1 in 10 people) increased appetite, dysgeusia (impairment of the sense of taste), dry mouth headache, dizziness insomnia (difficulty sleeping), abnormal dreams, somnolence (sleepiness) vomiting, diarrhoea, abdominal pain (stomach pain of discomfort), dyspepsia (indigestion), bloated or distended tummy (abdomen), flatulence (wind) hyperbilirubinaemia (increased levels of bilirubin in the blood) rash fatigue (extreme tiredness)
Croatian: Često (mogu se javiti u do 1 na 10 osoba) pojačan tek, disgeuzija (poremećaj osjeta okusa), suha usta glavobolja, omaglica nesanica (poteškoće sa spavanjem), neuobičajeni snovi, somnolencija (pospanost) povraćanje, proljev, bol u abdomenu (bol ili nelagoda u trbuhu), dispepsija (probavne tegobe), nadutost ili rastezanje trbuha, flatulencija (vjetrovi) hiperbilirubinemija (povišene razine bilirubina u krvi) osip iscrpljenost (izrazit umor)
English: The mechanism of interaction is inhibition of CYP2D6 by cobicistat.
Croatian: Mehanizam interakcije je inhibicija CYP2D6 koju uzrokuje kobicistat.
English: Uncommon (may affect up to 1 in 100 people) torsade de pointes (life threatening irregular heart beat) hypersensitivity (allergic reaction) anorexia (loss of appetite), weight loss, weight gain depression, anxiety, sleep disorder disorientation, amnesia (loss of memory) peripheral neuropathy (numbness, weakness, tingling or pain in the arms and legs) syncope (fainting), hypertension (high blood pressure) dyspnoea (shortness of breath) pancreatitis (inflammation of the pancreas), gastritis (inflammation of the stomach), stomatitis aphthous (mouth ulcers and cold sores) hepatitis (inflammation of the liver) angioedema (severe swelling of the skin and other tissues most often the lips or the eyes) urticaria (itchy rash), alopecia (unusual hair loss or thinning), pruritus (itching) muscle atrophy (muscle shrinkage), arthralgia (joint pain), myalgia (aching muscles) nephrolithiasis (formation of kidney stones), interstitial nephritis (kidney inflammation), hematuria (blood in the urine), proteinuria (excess protein in the urine), pollakiuria (increased frequency of urination), chronic kidney disease (how well your kidneys work) gynaecomastia (breast enlargement in men) chest pain, malaise (generally feeling unwell), fever asthenia (unusual tiredness or weakness) serious skin rashes (allergic reactions including rash, a high temperature, increased levels of liver enzymes seen in blood tests, an increase in a type of white blood cell [esosinophilia] and/or enlarged lymph nodes) (see section 2) gallbladder disorders (gallstones and gallbladder inflammation)
Croatian: Manje često (mogu se javiti u do 1 na 100 osoba) torsade de pointes (po život opasna nepravilnost srčanog ritma) preosjetljivost (alergijska reakcija) anoreksija (gubitak teka), gubitak tjelesne težine, povećanje tjelesne težine depresija, tjeskoba, poremećaj spavanja dezorijentacija, amnezija (gubitak pamćenja) periferna neuropatija (utrnulost, slabost, trnci ili bol u rukama i nogama) sinkopa (nesvjestica), hipertenzija (visok krvni tlak) dispneja (nedostatak zraka) pankreatitis (upala gušterače), gastritis (upala želuca), aftozni stomatitis (vrijedovi i afte u ustima) hepatitis (upala jetre) angioedem (teško oticanje kože i drugih tkiva , najčešće usana i očiju) urtikarija (osip koji svrbi), alopecija (neuobičajeno opadanje ili stanjivanje kose), pruritus (svrbež) mišićna atrofija (smanjenje mišića), artralgija (bol u zglobovima), mialgija (bol u mišićima) nefrolitijaza (stvaranje bubrežnih kamenaca), intersticijski nefritis (upala bubrega), hematurija (krv u mokraći), proteinurija (višak proteina u mokraći), polakizurija (učestalo mokrenje), kronična bubrežna bolest (kako dobro rade vaši bubrezi) ginekomastija (povećanje grudi u muškaraca) bol u prsištu, malaksalost (opće loše osjećanje), vrućica astenija (neuobičajen umor ili slabost) ozbiljni kožni osipi (alergijske reakcije koje uključuju osip, povišenu tjelesnu temperaturu, povišene razine jetrenih enzima u nalazima krvnih pretraga, povišen broj određene vrste bijelih krvnih stanica [eozinofilija] i/ili povećane limfne čvorove) (pogledajte dio 2.)
English: Cobicistat does not select any HIV resistance mutations, due to its lack of antiviral activity.
Croatian: Budući da kobicistat nema antivirusnu aktivnost, on ne izdvaja mutacije HIV virusa koje uzrokuju rezistenciju.
English: 25-O-desacetyl-rifabutin AUC
Croatian: 25-O-dezacetil-rifabutin AUC ↑990%
English: Atazanavir, an active component of EVOTAZ, has been detected in human milk.
Croatian: Atazanavir, djelatna tvar lijeka EVOTAZ pronađena je u majčinom mlijeku.
English: Midazolam and triazolam are extensively metabolized by CYP3A4.
Croatian: Midazolam i triazolam opsežno se metaboliziraju putem CYP3A4.
English: Cobicistat is a strong mechanism-based CYP3A inhibitor and is a CYP3A substrate.
Croatian: Kobicistat je snažan inhibitor CYP3A temeljeno na mehanizmu i supstrat za CYP3A.
English: No significant effect on atazanavir concentrations was observed.
Croatian: Nije opažen značajan učinak na koncentracije atazanavira.
English: Atazanavir plasma concentrations may decrease as a consequence of a reduction in cobicistat plasma concentrations, which may result in loss of therapeutic effect and development of resistance.
Croatian: Zbog sniženja plazmatskih koncentracija kobicistata mogu se sniziti i plazmatske koncentracije atazanavira, što za posljedicu može imati gubitak terapijskog učinka i razvoj rezistencije.
English: EVOTAZ should be used with caution in patients with mild hepatic impairment (see sections 4.2, 4.3 and 5.2).
Croatian: EVOTAZ treba primjenjivati uz oprez u bolesnika s blagim oštećenjem jetrene funkcije (vidjeti dijelove 4.2, 4.3 i 5.2).
English: Co-administration of EVOTAZ with proton pump inhibitors (PPIs) is not recommended due to the decreased solubility of atazanavir as intra-gastric pH increase with PPIs (see section 4.5).
Croatian: Ne preporučuje se istodobna primjena lijeka EVOTAZ s inhibitorima protonske pumpe jer se topljivost atazanavira smanjuje s povećanjem želučanog pH uzrokovanim primjenom inhibitora protonske pumpe (vidjeti dio 4.5).
English: Co-administration of tenofovir DF with cobicistat is expected to increase tenofovir plasma concentrations.
Croatian: Očekuje se da će istodobna primjena tenofovira DF i kobicistata povisiti plazmatske koncentracije tenofovira.
English: if you have type A or B haemophilia if you have problems with your kidneys or require haemodialysis.
Croatian: A ili B ako imate bubrežne tegobe koje zahtijevaju hemodijalizu.
English: Rifabutin 150 mg every other day/elvitegravir 150 mg once daily/cobicistat 150 mg once daily
Croatian: Rifabutin 150 mg svaki drugi dan/elvitegravir 150 mg jedanput na dan/kobicistat 150 mg jedanput na dan
English: Raltegravir 400 mg twice daily (atazanavir 400 mg)
Croatian: Raltegravir 400 mg dvaput na dan (atazanavir 400 mg)
English: (atazanavir 300 mg once daily with cobicistat 150 mg once daily)
Croatian: (atazanavir 300 mg jedanput na dan s kobicistatom 150 mg jedanput na dan)
English: Clinical monitoring may be needed upon co-administration with EVOTAZ.
Croatian: Možda će biti potrebno kliničko praćenje nakon istodobne primjene s lijekom EVOTAZ.
English: Cobicistat is a CYP3A substrate and is metabolised to a minor extent by CYP2D6.
Croatian: Kobicistat je supstrat za CYP3A i u manjoj se mjeri metabolizira putem CYP2D6.
English: Stevens-Johnson syndrome (SJS), erythema multiforme, toxic skin eruptions and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome have been reported with the use of atazanavir (see section 4.4).
Croatian: Kod primjene atazanavira prijavljeni su Stevens-Johnsonov sindrom (SJS), multiformni eritem, toksične kožne erupcije i medikamentozni osip praćen eozinofilijom i sistemskim simptomima (DRESS) (vidjeti dio 4.4).
English: If you develop signs or symptoms of kidney stones (pain in your side, blood in your urine, pain when you urinate), please inform your doctor immediately if you are taking oral contraceptives ("the Pill") to prevent pregnancy.
Croatian: Ako razvijete znakove ili simptome bubrežnih kamenaca (bol u slabinama, krv u mokraći, bol pri mokrenju), odmah o tome obavijestite svog liječnika.
English: Drospirenone/ethinyloestradiol 3 mg/0.02 mg single dose (atazanavir 300 mg once daily with cobicistat 150 mg once daily)
Croatian: Drospirenon/etinilestradiol 3 mg/0,02 mg u jednokratnoj dozi (atazanavir 300 mg jednom dnevno s kobicistatom150 mg jednom dnevno)
English: Co-administration of EVOTAZ with glecaprevir/pibrentasvir fixed dose combination is contraindicated because of the potential increase in the risk of ALT elevations due to a significant increase in glecaprevir and pibrentasvir plasma concentrations (see section 4.3).
Croatian: Istodobna primjena lijeka EVOTAZ s fiksnom kombinacijom glekaprevir/pibrentasvir je kontraindicirana zbog mogućeg povećanog rizika povišenja ALT-a zbog značajnog povišenja koncentracije glekaprevira i pibrentasvira u plazmi (vidjeti dio 4.3).
English: The effect of EVOTAZ on fertility in humans has not been studied.
Croatian: Nije ispitivan učinak lijeka EVOTAZ na plodnost ljudi.
English: No clinically relevant pharmacokinetic differences due to ethnicity have been identified for atazanavir or cobicistat.
Croatian: Nisu identificirane klinički značajne farmakokinetičke razlike uvjetovane etničkim podrijetlom koje bi bile povezane s atazanavirom ili kobicistatom.
English: There are limited data from the use of EVOTAZ in pregnant women.
Croatian: Podaci o primjeni lijeka EVOTAZ u trudnica su ograničeni.
English: Clinical monitoring of therapeutic effect and adverse events is recommended when these medicinal products are co-administered with EVOTAZ.
Croatian: Preporučuje se kliničko praćenje terapijskih učinaka i nuspojava pri istodobnoj primjeni navedenih lijekova s lijekom EVOTAZ.
English: Tenofovir disoproxil fumarate (tenofovir DF) 300 mg once daily (atazanavir 400 mg once daily)
Croatian: Tenofovirdizoproksilfumarat (tenofovir DF) 300 mg jedanput na dan (atazanavir 400 mg jedanput na dan)
English: Omeprazole 40 mg once daily (atazanavir 400 mg once daily, 2 hours after omeprazole)
Croatian: Omeprazol 40 mg jedanput na dan (atazanavir 400 mg jedanput na dan, 2 sata nakon omeprazola)
English: Cobicistat is metabolised via CYP3A (major)- and CYP2D6 (minor)-mediated oxidation and does not undergo glucuronidation.
Croatian: Kobicistat se metabolizira oksidacijom u kojoj posreduju CYP3A (glavni put) i CYP2D6 (sporedni put) te ne prolazi glukuronidaciju.
English: 14-OH clarithromycin Cmax ↓72%
Croatian: 14-OH klaritromicin Cmax ↓72% (↓76%
English: The mechanism of interaction is CYP3A4 inhibition by atazanavir, cobicistat and ketoconazole or itraconazole.
Croatian: Mehanizam interakcije je inhibicija CYP3A4 koju uzrokuju atazanavir, kobicistat i ketokonazol ili itrakonazol.
English: Co-administration of EVOTAZ with voxilaprevir-containing products is expected to increase the concentration of voxilaprevir.
Croatian: Očekivano je da istodobna primjena lijeka EVOTAZ s lijekovima koji sadrže voksilaprevir povisi koncentraciju voksilaprevira.
English: Amiodarone Dronedarone Quinidine Systemic lidocaine
Croatian: Amiodaron Dronedaron Kinidin
English: Dose related asymptomatic prolongations in PR interval with atazanavir, a component of EVOTAZ have been observed in clinical studies.
Croatian: U kliničkim su ispitivanjima opažena asimptomatska produljenja PR-intervala povezana s dozom atanazavira, sastavnicom lijeka EVOTAZ.
English: Atazanavir and cobicistat are metabolised by the hepatic system.
Croatian: Atazanavir i kobicistat se metaboliziraju putem jetre.
English: Efavirenz 600 mg single dose (cobicistat 150 mg once daily)
Croatian: Efavirenz 600 mg u jednokratnoj dozi (kobicistat 150 mg jedanput na dan)
English: 14-OH clarithromycin Cmin ↓62%
Croatian: 14-OH klaritromicin Cmin ↓62% (↓66%
English: Nephrolithiasis has been reported in patients receiving atazanavir (see section 4.8).
Croatian: U bolesnika koji su primali atazanavir prijavljena je nefrolitijaza (vidjeti dio 4.8).
English: Cobicistat is a selective, mechanism-based inhibitor of cytochromes P450 of the CYP3A subfamily.
Croatian: Kobicistat je selektivni inhibitor citokroma P450 podobitelji CYP3A temeljeno na mehanizmu.
English: Didanosine (enteric coated capsules) 400 mg single dose (atazanavir 400 mg once daily)
Croatian: Didanozin (želučanootporne kapsule) 400 mg u jednokratnoj dozi (atazanavir 400 mg jedanput na dan)
English: Co-administration of salmeterol with EVOTAZ is not recommended (see section 4.4).
Croatian: Ne preporučuje se istodobna primjena salmeterola i lijeka EVOTAZ (vidjeti dio 4.4).
English: Co-administration with EVOTAZ has the potential to produce serious and/or life-threatening adverse reactions.
Croatian: Istodobna primjena s lijekom EVOTAZ može uzrokovati ozbiljne i/ili po život opasne nuspojave.
English: Cobicistat, a component of EVOTAZ, has been shown to decrease estimated creatinine clearance due to inhibition of tubular secretion of creatinine.
Croatian: Pokazalo se da kobicistat, sastavnica lijeka EVOTAZ, smanjuje procijenjeni klirens kreatinina zbog inhibicije tubularne sekrecije kreatinina.
English: AUC ↑247% (↑229% ↑267%) Cmax ↑216% (↑200% ↑233%) Cmin ↑273% (↑254% ↑293%)
Croatian: AUC ↑247% (↑229% ↑267%) Cmax ↑216% (↑200% ↑233%)
English: Co-administration of EVOTAZ with medicinal products that inhibit CYP3A may result in increased plasma concentration of atazanavir and/or cobicistat.
Croatian: Istodobna primjena lijeka EVOTAZ i lijekova koji inhibiraju CYP3A može povisiti plazmatske koncentracije atazanavira i/ili kobicistata.
English: Naloxone AUC: ↓28% Naloxone Cmax: ↓28%
Croatian: Nalokson AUC: ↓28% Nalokson Cmax: ↓28%